secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2022-12-02T23:59:59+00:00
Accession:  0001104659-22-124193
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 1.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar adopts amended bylaws and indemnification agreements for directors and officers
--------------------------------------------------------------------------------

- Bylaws amended to include exclusive forum provision and clarify director removal only for cause with majority vote.
- Special meetings of stockholders and stockholder proposals subject to enhanced procedural mechanics.
- Indemnification agreements with each director and executive officer provide full indemnity to extent permitted by Delaware law.
- Company also updated bylaws to reflect current name, DGCL updates, and emergency procedures under Section 110.
- No financial or operational changes reported; governance-only filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465922124193/0001104659-22-124193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465922124193/tm2231728d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-124193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer